Abbott To Cut Rx Development Costs In Half By Increasing Candidate Attrition
Executive Summary
Abbott believes it can cut the cost of drug development in half by increasing the rate of attrition in the discovery phase, the company said Feb. 9 at a drug development summit sponsored by R&D Directions in Phoenix